{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:40:40Z","timestamp":1781188840987,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jjcc.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:26:20Z","timestamp":1569457580000},"page":"233-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Recovery of left ventricular dysfunction after sacubitril\/valsartan: predictors and management"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-7739","authenticated-orcid":false,"given":"Hung-Yu","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2500-3182","authenticated-orcid":false,"given":"Kuan-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Cai","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Ning","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-1486","authenticated-orcid":false,"given":"Hao-Neng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-1963","authenticated-orcid":false,"given":"Kuan-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5023-1611","authenticated-orcid":false,"given":"Wei-Hsian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2019.08.005_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0010","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).","volume":"316","author":"The CONSENSUS trial study group","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0020","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0035","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0735-1097(99)00157-6","article-title":"Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography","volume":"34","author":"Bax","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0055","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/01.CIR.0000065226.24159.E9","article-title":"Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure","volume":"107","author":"St John Sutton","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0065","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0070","first-page":"e282","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0075","first-page":"108","article-title":"Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh","year":"2017","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10557-019-06858-0","article-title":"Sacubitril\/valsartan in real-life practice: experience in patients with advanced heart failure and systematic review","volume":"33","author":"Moliner-Ab\u00f3s","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0085","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199705083361903","article-title":"Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction","volume":"336","author":"Vasan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0735-1097(83)80316-7","article-title":"A placebo-controlled trial of captopril in refractory chronic congestive heart failure","volume":"2","author":"Captopril Multicenter Research Group","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0095","first-page":"VI65","article-title":"Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group","volume":"87","author":"Wong","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0100","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1067\/mhj.2002.121269","article-title":"Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging","volume":"143","author":"Dubach","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0110","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0115","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.amjcard.2012.08.056","article-title":"Left ventricular reverse remodeling in long-term (&12 years) survivors with idiopathic dilated cardiomyopathy","volume":"111","author":"Matsumura","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00380-015-0648-2","article-title":"Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy","volume":"31","author":"Ikeda","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","article-title":"Sacubitril\/valsartan in daily clinical practice: data from a prospective registry","volume":"73","author":"Vicent","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0135","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijcard.2016.09.078","article-title":"Predictors of response to cardiac resynchronization therapy: a systematic review","volume":"225","author":"Rickard","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0145","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0150","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.08.005_bib0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508719302643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:02:40Z","timestamp":1760274160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508719302643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0914508719302643"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.08.005","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recovery of left ventricular dysfunction after sacubitril\/valsartan: predictors and management","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}